Kaposi Sarcoma Market Size, Share & Trends Analysis Report By Type (Epidemic, Endemic, Classic, Latrogenic), By Diagnostic, By Treatment, By End-use, By Region, And Segment Forecasts, 2023 - 2030

Kaposi Sarcoma Market Size & Trends

The global kaposi sarcoma market size was valued at USD 110.48 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 2.89% from 2023 to 2030. This can be attributed to the substantial increase in the number of people affected with Kaposi sarcoma globally. Furthermore, various end-users, including clinics, diagnostic centers, and hospitals, are expected to exhibit potential demand in the worldwide market for Kaposi sarcoma diagnostics and treatment.

The rising number of patients undergoing organ transplantation surgical procedures who are at high risk of KS and the increasing prevalence of patients with KS worldwide. As per the study published in the NCBI in 2021, it is more common in males who have sex with men (MSM) and in specific locations of the world, such as countries bordering the Mediterranean and Sub-Saharan Africa. In addition, in Uganda, the prevalence of KS was high in early childhood, with an annual prevalence rate of 50%.  Thus, the increasing prevalence of patients with Kaposi Sarcoma is anticipated to drive demand for treatment over the forecast period, thereby driving market growth.

Furthermore, people with kidney transplant recipients are at high risk of developing Kaposi sarcoma due to human herpes virus type 8 reactivation and immunosuppression. As per the United Network for Organ Sharing (UNOS) Statistics 2022, more than 25,000 kidney transplants were operated in the U.S. End-stage renal disease (ESRD) is a major contributor to the rise in kidney transplants globally. Thus, the increasing prevalence of ESRD is anticipated to lead to an increase in kidneys. transplants, thereby driving market growth.

Moreover, the rising incidence of Kaposi sarcoma among black men over white men is also a key factor driving market growth. As per a research study published in JNCI Cancer Spectrum in 2022, Non-Hispanic Black males (46.0%) had the highest diagnosis rate of Kaposi sarcoma cases, followed by non-Hispanic White men (24.1%), men of other races (3.0%), and Hispanic men (25.1%). Thus, the growing prevalence of Kaposi sarcoma globally is expected to drive demand for diagnosis and treatment, thereby driving market growth.

Type Insights

On the basis of the type, the market is segmented into the epidemic, endemic, classic, and latrogenic. The epidemic segment held the largest market share in 2022. This can be attributed to a high incidence rate of HIV AIDS associated Kaposi sarcoma. According to the American Cancer Society, the AIDS associated Kaposi sarcoma occurs at a rate of about 6 cases per million population annually. It is more common in the African American population than the white population in the U.S. Thus, increasing prevalence of AIDS associated Kaposi sarcoma is projected to fuel demand for Kaposi sarcoma treatment in the coming years.

Diagnostics Insights

Based on the diagnostics, the Kaposi sarcoma market is segmented into bronchoscopy, gastrointestinal endoscopy, biopsy, and others. The biopsy segment held the largest market share in 2022. This can be attributed to the high demand for bone biopsies due to the increasing cancer incidence. As per the MJH Life Sciences Statistics, more than 700,000 biopsies are performed yearly in the U.S. Thus, technological advancement in biopsy is expected to boost segment growth over the forecast period.

Treatment Insights

Based on the treatment, the Kaposi sarcoma market is segmented into radiation therapy, immunotherapy, chemotherapy, Highly Active Antiretroviral Therapy (HAART), and others. The HAART segment held the largest market share in 2022. This can be attributed to the high adoption of highly active antiretroviral therapy (HAART) for treating Kaposi sarcoma. It is managed and treated with highly active antiretroviral treatment (HAART). It is made up of many pharmaceuticals that belong to the antiretroviral medicine class. The research and development of new HAART medicines is expected to drive segment growth.

End-use Insights

Based on the end use, the Kaposi Sarcoma market is segmented into hospitals, specialty centers, homecare, and others. The hospitals segment held the largest market share in 2022. This can be attributed to the increasing number of hospital admissions for organ transplants. For prospective transplant patients, hospitals are the first place they should contact to determine any contraindications and evaluate their general health. According to the American Kidney Fund Statistics, over 106,000 people are on the national waiting transplant list, with 92,000 waiting for a kidney. The high number of patients on the kidney transplant waiting list is anticipated to increase hospital admissions in the coming years, driving market growth.

Regional Insights

North America dominated the market in 2022. This can be attributed to the growing number of product approvals, several market participants, the high number of R&D efforts undergoing treatment, and the diagnosis of Kaposi sarcoma. Furthermore, the rising incidence of HIV and Kaposi sarcoma supports regional market expansion. Around 30,635 people in the U.S. and its dependent countries were diagnosed with HIV in 2020, according to statistics released by the CDC in September 2022. The aforementioned statistics indicates a high prevalence of HIV in the nation, hence driving demand for diagnosis & treatment. Asia-Pacific is expected to witness the fastest CAGR over the forecast period.

Key Companies & Market Share Insights

Key players operating in the market are Bristol-Myers Squibb Company, Pfizer Inc., Navidea Biopharmaceuticals, Inc., Merck & Co., Inc., and Baxter Inc. The market participants are constantly working towards new M&A activities, product development, and other strategic alliances to gain new market avenues.

The following are some instances of strategic initiatives:

• In February 2023, researchers from the UNC School of Medicine discovered a protein that allows the Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV) to cause and spread disease.

• In August 2022, Weill Cornell Medicine and Cornell Engineering designed, developed, and deployed a portable diagnostic device in clinical tests in Uganda to diagnose new cases of Kaposi sarcoma.